Alogabat

Alogabat is a positive allosteric modulator (PAM) and agonist (Ki GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold) . GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction[1][2].

Product Specifications

CAS Number

[2230009-48-8]

Product Name Alternative

RG-7816; RO-7017773

UNSPSC

12352005

Target

GABA Receptor

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/alogabat.html

Concentration

10mM

Purity

99.93

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

O=C(C1=NN=C(OCC2=C(C)ON=C2C3=CC=C(C)N=C3)C=C1)NC4CCOCC4

Molecular Formula

C21H23N5O4

Molecular Weight

409.44

References & Citations

[1]Bernd Buettelmann, et al. Preparation of new isoxazolyl ether derivatives as GABAA α5 receptor positive allosteric modulators (PAMs) . World Intellectual Property Organization, WO2018104419 A1 2018-06-14.|[2]Belew Mekonnen, et al. Benzazepine derivatives for the treatment of cognitive impairment and their preparation. World Intellectual Property Organization, WO2024039886 A1 2024-02-22.